Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mutations in EPHB4 cause human venous valve aplasia
Oliver Lyons, James Walker, Christopher Seet, Mohammed Ikram, Adam Kuchta, Andrew Arnold, Magda Hernández-Vásquez, Maike Frye, Gema Vizcay-Barrena, Roland A. Fleck, Ashish S. Patel, Soundrie Padayachee, Peter Mortimer, Steve Jeffery, Siren Berland, Sahar Mansour, Pia Ostergaard, Taija Makinen, Bijan Modarai, Prakash Saha, Alberto Smith
Oliver Lyons, James Walker, Christopher Seet, Mohammed Ikram, Adam Kuchta, Andrew Arnold, Magda Hernández-Vásquez, Maike Frye, Gema Vizcay-Barrena, Roland A. Fleck, Ashish S. Patel, Soundrie Padayachee, Peter Mortimer, Steve Jeffery, Siren Berland, Sahar Mansour, Pia Ostergaard, Taija Makinen, Bijan Modarai, Prakash Saha, Alberto Smith
View: Text | PDF
Research Article Angiogenesis Development

Mutations in EPHB4 cause human venous valve aplasia

  • Text
  • PDF
Abstract

Venous valve (VV) failure causes chronic venous insufficiency, but the molecular regulation of valve development is poorly understood. A primary lymphatic anomaly, caused by mutations in the receptor tyrosine kinase EPHB4, was recently described, with these patients also presenting with venous insufficiency. Whether the venous anomalies are the result of an effect on VVs is not known. VV formation requires complex “organization” of valve-forming endothelial cells, including their reorientation perpendicular to the direction of blood flow. Using quantitative ultrasound, we identified substantial VV aplasia and deep venous reflux in patients with mutations in EPHB4. We used a GFP reporter in mice to study expression of its ligand, ephrinB2, and analyzed developmental phenotypes after conditional deletion of floxed Ephb4 and Efnb2 alleles. EphB4 and ephrinB2 expression patterns were dynamically regulated around organizing valve-forming cells. Efnb2 deletion disrupted the normal endothelial expression patterns of the gap junction proteins connexin37 and connexin43 (both required for normal valve development) around reorientating valve-forming cells and produced deficient valve-forming cell elongation, reorientation, polarity, and proliferation. Ephb4 was also required for valve-forming cell organization and subsequent growth of the valve leaflets. These results uncover a potentially novel cause of primary human VV aplasia.

Authors

Oliver Lyons, James Walker, Christopher Seet, Mohammed Ikram, Adam Kuchta, Andrew Arnold, Magda Hernández-Vásquez, Maike Frye, Gema Vizcay-Barrena, Roland A. Fleck, Ashish S. Patel, Soundrie Padayachee, Peter Mortimer, Steve Jeffery, Siren Berland, Sahar Mansour, Pia Ostergaard, Taija Makinen, Bijan Modarai, Prakash Saha, Alberto Smith

×

Figure 6

Failure of VFCs to project into vessel lumen and abnormal integrin expression.

Options: View larger image (or click on image) Download as PowerPoint
Failure of VFCs to project into vessel lumen and abnormal integrin expre...
(A) Semithin longitudinal sections of P0 femoral veins showed protruding VFCs in littermate controls, but no protruding cells were seen after homozygous Efnb2 deletion. 3D reconstructions of semithin sections show protruding VFCs (arrowheads) in controls only. The schematic indicates the orientation of the semithin sections. (B) A significant reduction in the mean number of sections showing protruding cells was identified (≥ 60 sections were analyzed per sample, *P < 0.05 by 2-tailed t test, n = 3 VV per group, data are shown as mean ± SEM). (C) Integrin α9 was expressed in a ring around the organized VFCs in littermate controls (white arrowheads), but after homozygous Efnb2 deletion, the localization of integrin α9 expression was disrupted and chaotic (P < 0.05, χ2 test of the proportion of VVs showing normal vs. disrupted integrin α9 expression pattern, n ≥ 6 VV per group). (D) VFC polarity (indicated by white arrows) was examined by costaining for Prox1 (magenta), PECAM1 (blue), and Golgi (green). Polarity was determined for individual VFCs using 0.5-μm sections, and a Z projection of 2–4 confocal sections shown on the right (area enlarged outlined by dotted box,). In littermate controls, cells in the central region of the vein were aligned with the line of organized VFCs, whereas after homozygous Efnb2 deletion, cell alignment was chaotic. P < 0.05, χ2 test of the proportion of VVs showing normal vs. chaotic VFC alignment, n ≥ 8 VV per group. Yellow arrows indicate VFCs on the posterior vein wall. Scale bars in A, C, and D: 20 μm. C and D are oriented as shown in Figure 2A. VFCs, valve-forming cells; VVs, venous valves.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts